[Pregabalin (Lyrica) and neuropathic pain syndromes].
Pregabalin is a novel central nervous system (CNS) drug with no interaction at benzodiazepine or GABA receptor. Its mechanism of action is correlated with its high affinity for the alpha/delta submit of the voltage-dependant CNS calcium channel. Pregabalin is rapidly absorbed with at least 90% bioavailable irrespective of dose, does not bind to plasma proteins and is excreted virtually unchanged by the kidneys. Pharmacokinetics are linear and predictable across the therapeutic dose range (150-600 mg/ day). Pregabalin is indicated, like gabapentin, in the treatment of neuropathic pain syndromes like post-herpetic neuralgia (PHN) and diabetic polyneuropathy (DPN). Efficacy in other neuropathic pain syndromes need further investigations. This paper emphasizes advantages and disadvantages on a clinical point of view.
Jacquy
J
J
Service de Neurologie, C.H.U. de Charleroi.
Lossignol
D
D
Sternon
J
J
D000042:Absorption; D000700:Analgesics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001682:Biological Availability; D015220:Calcium Channels / Q000187:drug effects; D003929:Diabetic Neuropathies / Q000188:drug therapy; D006801:Humans; D009437:Neuralgia / Q000188:drug therapy*; D051474:Neuralgia, Postherpetic / Q000188:drug therapy; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
D000700:Analgesics; D015220:Calcium Channels; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid